Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cell Therapeutics Inc    

CELL THERAPEUTICS INC
Mes dernières consult.
Most popular
  Report  
SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Cell Therapeutics Inc : Five Star Equities Issues New Research Reports on CTIC, PACB, SEED and STML

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/21/2014 | 02:50pm CEST

Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.

Cell Therapeutics Inc. (NASDAQ: CTIC) shares jumped 13.75 percent to close at $3.64 a share Friday. The stock traded between $3.40 and $3.79 on volume 13.56 million shares traded. Earlier this month, the company received notification from the FDA that the partial clinical hold on Tosedostat has been removed and all studies underway may continue. Shares of Cell Therapeutics have gained approximately 140.0 percent in the past year.

Get more information on Cell Therapeutics free access to the in-depth equity report at:
www.FiveStarEquities.com/CTIC

Pacific Biosciences of California (NASDAQ: PACB) shares spiked 14.44 percent to close at $6.50 a share Friday. The stock traded between $5.65 and $6.97 on volume 2.70 million shares traded. The company is scheduled to release Fourth Quarter and Year End 2013 results on Tuesday, February 4th. Shares of Pacific Biosciences of California have gained approximately 160.0 percent in the past year.

Get more information on Pacific Biosciences and free access to the in-depth equity report at:
www.FiveStarEquities.com/PACB

Origin Agritech Ltd. (NASDAQ: SEED) shares surged 18.81 percent to close at $2.40 a share Friday. The stock traded between $2.03 and $2.55 on volume of 2.70 million shares traded. The company recently reported an operating income of RMB18.16 million for the fiscal year 2013, compared to an operating loss of RMB (3.47) million a year ago. Shares of Origin Agritech have gained approximately 56.0 percent in the past year.

Get more information on Origin Agritech and free access to the in-depth equity report at:
www.FiveStarEquities.com/SEED

Stemline Therapeutics Inc. (NASDAQ: STML) shares soared 39.50 percent to close at $30.44 a share Friday. The stock traded between $22.00 and $30.45 on volume 1.40 million shares traded. Ivan Bergstein, M.D., Stemline's CEO, presented at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014. Shares of Stemline Therapeutics have gained approximately 150.0 percent in the past year.

Get more information on Stemline Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/STML

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Five Star Equities
[email protected]


© Accesswire 2014
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELL THERAPEUTICS INC
06/18CTI BIOPHARMA : to Present at the JMP Securities 2018 Life Sciences Conference
AQ
05/25CTI BIOPHARMA CORP : Other Events (form 8-K)
AQ
05/22CTI BIOPHARMA CORP. (NASDAQ : CTIC) Files An 8-K Departure of Directors or Certa..
AQ
05/21CTI BIOPHARMA CORP : Change in Directors or Principal Officers, Submission of Ma..
AQ
05/09CTI BIOPHARMA : Reports First Quarter 2018 Financial Results
AQ
05/03CTI BIOPHARMA : 1Q Earnings Snapshot
AQ
05/03CTI BIOPHARMA : Management's Discussion and Analysis of Financial Condition and ..
AQ
05/03CTI BIOPHARMA CORP : Results of Operations and Financial Condition, Financial St..
AQ
05/02CTI BIOPHARMA : to Report First Quarter 2018 Financial Results on May 3, 2018
AQ
03/26CTI BIOPHARMA CORP. (NASDAQ : CTIC) Files An 8-K Amendments to Articles of Incor..
AQ
More news
Financials ($)
Sales 2018 13,2 M
EBIT 2018 -52,4 M
Net income 2018 -49,5 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 22,1x
Capi. / Sales 2019 14,2x
Capitalization 292 M
Technical analysis trends CELL THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
 
Mean consensus BUY
Number of Analysts 4
Average target price 7,25 $
Spread / Average Target 48%
EPS Revisions
Managers
NameTitle
Adam R. Craig President, Chief Executive Officer & Director
Laurent Fischer Chairman
Bruce J. Seeley COO, Secretary, Chief Administrative Officer & EVP
David H. Kirske Chief Financial Officer & Executive VP
Jack W. Singer EVP, Chief Scientific & Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
CELL THERAPEUTICS INC292
CELLTRION, INC.--.--%33 064
IQVIA HOLDINGS INC6.98%21 789
LONZA GROUP2.35%20 356
INCYTE CORPORATION-22.94%15 565
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 581